Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1037 results
January 2016
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the USCosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
-
Media ReleaseNovartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface OncologyAgreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment…
-
Media ReleaseNovartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPDThe Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
December 2015
-
Media ReleaseNovartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patientsCosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
-
Media Release300 million child-friendly antimalarial treatments supplied without profit by NovartisCoartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
-
Media ReleaseSandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanerceptSandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes…
-
Media ReleaseNovartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on…
-
Media ReleasePhase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference productPROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met…
-
Media ReleaseNovartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutationsStudy in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
-
Media ReleaseNovartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphomaOverall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019…
-
Media ReleaseNovartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia veraData suggest myelofibrosis (MF) patients treated with Jakavi® (ruxolitinib) after 5 years lived longer despite crossover from best available therapy after week 48[1] Phase III results show…
-
Media ReleaseNovartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patientsMore than 50 abstracts will be presented, including data on Afinitor® and investigational compounds for advanced breast cancer, showing pipeline strength Presentations highlight results of…
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 87
- › Next page